The results correspond to our data, suggesting that PD-1 expression on tumor cells plays a pivotal role in DLBCL tumor microenvironment and contributes to aggressive clinical outcomes, as well as EBV status, and may be an effective therapeutic target. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.